ACTION PROFILE OF THE RAPID ACTING INSULIN ANALOG - HUMAN INSULIN B28ASP

The time-action profile of the human insulin analogue B28Asp, which di splays faster absorption rates from subcutaneous tissue compared to so luble human insulin, was studied under euglycaemic glucose clamp condi tions (blood glucose 5.0 mmol l-1) in 14 healthy male volunteers. Subc utaneous injection of 0.15 U kg-1 body weight (range 9.5-14.3 U) of th e insulin analogue or soluble human insulin resulted in half-maximal g lucose infusion rates (after subtraction of mean baseline glucose infu sion rates) that were reached significantly earlier after injection of B28Asp (45 +/- 11 (SD) min) as compared to human insulin (58 +/- 25 m in, p < 0.05). Forty-five and 60 min after injection of human insulin, glucose infusion rates had increased by 3.4 +/- 1.8 and 4.8 +/- 2.3 m g min-1 kg-1 above baseline glucose infusion rates, reflecting 30 +/- 15 and 42 +/- 17 % of maximal action of 10.6 +/- 2.7 mg min-1 kg-1. Fo llowing the injection of B28Asp, glucose infusion rates increased by 6 .3 +/- 2.7 after 45 min and by 7.9 +/- 2.8 mg min-1 kg-1 after 60 min above baseline glucose infusion rates, reflecting 64 +/- 28 % and 81 /- 26 % of maximal action of human soluble insulin (p < 0.001). Peak g lucose infusion rates after injection of B28Asp were significantly hig her and were reached earlier than after subcutaneous injection of solu ble human insulin (p < 0.05 and p < 0.001). The human insulin analogue B28Asp showed a significantly faster onset of action as compared to s oluble human insulin.